Loading organizations...
§ Venture Capital · San Francisco, CA, USA
Organization researching and developing human augmentation technologies, exploring neurotechnology and its applications.
Key people at Human Augmentation Syndicate.
Human Augmentation Syndicate was founded in 2016 by Ariel Poler (Founder).
Human Augmentation Syndicate operates within the emerging field of human augmentation, though specific details regarding its operational scope and headquarters remain undisclosed. The organization's name suggests a focus on enhancing human capabilities through technology, a sector attracting increasing interest from various stakeholders. However, publicly available information concerning its precise business model, any completed funding rounds, or key personnel is not readily accessible. The syndicate's operational scale, including employee count or user base, has not been disclosed in any public records, nor have any specific details regarding its customer base, portfolio companies, or lead investors been identified. The founding year and individuals associated with its establishment are also not publicly known, making a comprehensive profile challenging to construct based on currently available information.
The Human Augmentation Syndicate is an AngelList-based investment syndicate focused on backing early-stage startups that are building technologies to enhance human capabilities. Its mission is to accelerate the development of human augmentation—technologies that extend, restore, or upgrade human physical, cognitive, and sensory functions—by connecting visionary founders with experienced angel investors and strategic partners.
The syndicate’s investment philosophy centers on the belief that the next decade will be defined by breakthroughs in neural interfaces, bioelectronics, wearable systems, and AI-driven health technologies. It targets companies in core human augmentation domains such as neurotechnology, prosthetics, exoskeletons, brain-computer interfaces, and digital health platforms. By concentrating on this frontier, the syndicate plays a catalytic role in shaping a new wave of startups that sit at the intersection of biology and technology, helping to de-risk and scale innovations that have the potential to redefine healthcare, work, and daily life.
The Human Augmentation Syndicate was founded by Ariel Poler, a seasoned entrepreneur and investor with deep roots in technology and innovation. Poler launched the syndicate on AngelList as a thematic vehicle to channel capital and expertise into startups pioneering human augmentation technologies. His background and network in deep tech and health innovation positioned him to identify early signals in fields like neural engineering and bio-augmentation.
The syndicate gained early visibility through its lead participation in BIOS’ $4.5M seed round in 2018, marking BIOS as the first company in the world to automate the identification of neural signals regulating organ function. This investment underscored the syndicate’s focus on foundational, platform-like technologies rather than narrow point solutions. Since then, it has become a signal investor for startups working on “Human 2.0” technologies, attracting co-investors from top-tier funds and strategic angels who share its conviction in the transformative potential of human augmentation.
The Human Augmentation Syndicate is riding the convergence of several powerful trends: the maturation of neural engineering, the miniaturization of bioelectronics, the rise of AI in healthcare, and the growing demand for technologies that extend human performance and longevity. These forces are fueling what is increasingly being called the “Human 2.0” era, where technology is no longer just external tools but integrated into the body and nervous system.
Timing is critical: as regulatory pathways for implantables and neural devices begin to clarify (e.g., FDA’s increased engagement with neurotech), and as aging populations drive demand for assistive and restorative technologies, the market for human augmentation is expanding rapidly. The syndicate sits at the heart of this shift, backing companies that are building the foundational interfaces—like neural “USB ports for the body”—that will enable future applications in prosthetics, organ control, mental health, and beyond.
By focusing on platform technologies rather than isolated applications, the syndicate helps shape an ecosystem where multiple use cases can emerge from a single interface layer. This positions it not just as a passive investor, but as an architect of the human augmentation stack, influencing how startups approach design, data, and clinical validation in this emerging field.
Looking ahead, the Human Augmentation Syndicate is well-positioned to become a defining node in the human augmentation ecosystem. As neural interfaces, bioelectronics, and AI-driven health tools move from labs to clinics and consumer markets, the syndicate’s early bets on foundational technologies like BIOS’ neural interface could yield outsized impact—and returns.
The next phase will likely see the syndicate expanding its portfolio into adjacent areas: cognitive augmentation, sensory enhancement, and AI-powered personalized medicine platforms. It may also evolve into a more structured fund or SPV vehicle as the space matures and institutional capital begins to flow more heavily into human augmentation.
Ultimately, the syndicate’s influence will grow not just through financial returns, but by shaping the norms, standards, and expectations for what human augmentation can—and should—become. In a world where the line between human and machine is blurring, the Human Augmentation Syndicate is helping to write the first chapters of that future.
Key people at Human Augmentation Syndicate.
Human Augmentation Syndicate was founded in 2016 by Ariel Poler (Founder).
